Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Tuvusertib (M1774) in Advanced Solid Tumors
NCT05691491Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tuvusertib in solid tumor, colorectal cancer (CRC), sponsored by National Cancer Institute. Started Sep 2023; status: recruiting.
02
Drugs
tuvusertib
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05691491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691491.